Crescent Biopharma (Nasdaq: CBIO) granted stock options as equity inducement awards to five non-executive employees under its 2025 Employment Inducement Incentive Award Plan.
The awards cover 129,075 shares with a 10-year term and a per-share exercise price of $18.52, vesting over four years, subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CBIO
+6.23%
5 alerts
+6.23%Session close to close
+2.6%Peak in 1 min
$562.74MMarket Cap
0.5xRel. Volume
In the May 13 session, CBIO gained 6.23%, reflecting a notable positive market reaction.
Argus tracked a peak move of +2.6% during that session.
Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
The stock moved +6.2% in the session following this news. A strong positive reaction aligns with Cre...
Analysis
The stock moved +6.2% in the session following this news. A strong positive reaction aligns with Crescent’s history of market sensitivity even to routine updates, such as prior inducement grants that coincided with moves up to 9.63%. However, today’s awards add 129,075 options at an exercise price of $18.52, and shares already trade at the 52-week low. Investors monitoring sustainability may weigh ongoing option issuance, broader biotech sentiment, and how price behaves relative to the $13.52 200-day moving average.
Key Figures
Option shares granted:129,075 sharesExercise price:$18.52Option term:10 years+5 more
8 metrics
Option shares granted129,075 sharesAggregate options granted to five non-executive employees
Exercise price$18.52Exercise price equals Nasdaq closing price on May 11, 2026
Option term10 yearsTerm of inducement stock options under the Inducement Plan
Initial vesting1/4 of sharesVests on first anniversary of each employee’s start date
Ongoing vesting1/48 of sharesVests monthly after first anniversary, subject to continuous service
Current share price$18.46Price before news; 24h move -1.28%
52-week high$27.41Pre-news 52-week high level
52-week low$18.46Pre-news 52-week low; equal to current price
Inducement option awards totaling 45,675 shares to two non-executive employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent Crescent news, including prior inducement grants and earnings, has generally seen price moves that align directionally with the perceived tone of the announcements, with routine HR-related awards often met by modest or mixed reactions.
Recent Company History
Over the past few months, Crescent issued several routine updates. On March 6, 2026, 45,675-share inducement awards drew a small -0.41% move. Further inducement grants on March 27 and April 24 (totaling 35,325 and 12,525 shares, respectively) coincided with gains of 9.63% and 1.41%. Q1 2026 results on April 29, highlighting $189.2M cash and funding into 2028, were followed by a 6.83% rise. An investor conference announcement on May 6 saw a marginal -0.11% move. Today’s inducement awards fit this pattern of incremental, HR-focused updates.
"approved the grant of options to purchase an aggregate of 129,075 shares... as equity inducement awards"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
Nasdaq Listing Rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4). The options were granted with a 10-year term"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"a 10-year term and an exercise price equal to $18.52, the closing price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 129,075 shares of the Company’s ordinary shares to five non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on May 11, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to $18.52, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on May 11, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
What inducement stock option awards did Crescent Biopharma (CBIO) grant on May 11, 2026?
Crescent Biopharma granted options to purchase an aggregate 129,075 ordinary shares as equity inducement awards. According to Crescent Biopharma, these options were granted to five non-executive employees under the 2025 Employment Inducement Incentive Award Plan, as amended.
What is the exercise price and term of the new Crescent Biopharma (CBIO) inducement options?
The inducement options have a 10-year term and an exercise price of $18.52 per share. According to Crescent Biopharma, this price equals the closing price of its ordinary shares on Nasdaq on May 11, 2026.
How do Crescent Biopharma (CBIO) inducement option awards vest for new employees?
The options vest 25% on the first anniversary of each employee’s start date, then monthly thereafter. According to Crescent Biopharma, one-forty-eighth of the shares vest monthly over the remaining three years, subject to continuous service.
Why did Crescent Biopharma (CBIO) issue inducement awards under Nasdaq Listing Rule 5635(c)(4)?
Crescent Biopharma issued the options as equity inducement awards material to each employee’s acceptance of employment. According to Crescent Biopharma, the grants were approved by the Board’s Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4).
Who received the Crescent Biopharma (CBIO) inducement stock options announced in May 2026?
Five non-executive employees received the inducement option grants from Crescent Biopharma. According to Crescent Biopharma, the awards were made under the 2025 Employment Inducement Incentive Award Plan to support recruitment and retention of these new hires.
